Although pancreatic neuroendocrine tumors (PanNETs) have long been considered benign tumors, they in fact have considerable malignant potential. This Review outlines the clinicopathological features of PanNETs and the latest advances in our knowledge of the biology of these tumors. The authors also outline how mutational analysis will affect personalized therapy and discuss the approved new targeted agents tailored specifically towards PanNETs.
- Roeland F. de Wilde
- Barish H. Edil
- Anirban Maitra
